Carlos Cruchaga

List of Publications by Citations

311 papers	25,263 citations	69 h-index	156 g-index
389 ext. papers	32,466 ext. citations	11.2 avg, IF	6.03 L-index

#	Paper	IF	Citations
311	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*, **2013**, 45, 1452-8	36.3	2714
310	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1088-93	36.3	2018
309	TREM2 variants in Alzheimer's disease. *New England Journal of Medicine*, **2013**, 368, 117-27	59.2	1805
308	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
307	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature Genetics*, **2011**, 43, 436-41	36.3	1367
306	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
305	Human apoE isoforms differentially regulate brain amyloid- peptide clearance. *Science Translational Medicine*, **2011**, 3, 89ra57	17.5	721
304	Analysis of shared heritability in common disorders of the brain. *Science*, **2018**, 360,	33.3	666
303	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nature Genetics*, **2018**, 50, 524-537	36.3	536
302	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*, **2017**, 549, 523-527	50.4	520
301	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
300	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nature Medicine*, **2019**, 25, 277-283	50.5	375
299	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature*, **2014** , 505, 550-554	50.4	345
298	Alzheimer's disease genetics: from the bench to the clinic. *Neuron*, **2014**, 83, 11-26	13.9	308
297	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS ONE*, **2010**, 5, e13950	3.7	276
296	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. *Neuron*, **2013**, 78, 256-68	13.9	255
295	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. *Nature Neuroscience*, **2017**, 20, 1052-1061	25.5	228

294	Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain*, **2015**, 138, 3673-84	11.2	227
293	Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. *Nature Genetics*, **2012**, 44, 1349-54	36.3	223
292	Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. *PLoS ONE*, **2012**, 7, e50976	3.7	211
291	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
290	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathologica*, **2016**, 131, 925-33	14.3	201
289	Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS ONE*, **2012**, 7, e31039	3.7	201
288	Coding variants in TREM2 increase risk for Alzheimer's disease. *Human Molecular Genetics*, **2014**, 23, 5838-46	5.6	194
287	TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. *JAMA Neurology*, **2014**, 71, 449-53	17.2	188
286	Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. *Molecular Psychiatry*, **2009**, 14, 501-10	15.1	179
285	A novel Alzheimer disease locus located near the gene encoding tau protein. *Molecular Psychiatry*, **2016**, 21, 108-17	15.1	175
284	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. *Human Molecular Genetics*, **2012**, 21, 3500-12	5.6	174
283	Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. *Human Molecular Genetics*, **2009**, 18, 3125-35	5.6	161
282	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*, **2020**, 26, 398-407	50.5	160
281	Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. *Lancet Neurology, The*, **2016**, 15, 174-184	24.1	159
280	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. *Human Molecular Genetics*, **2012**, 21, 4558-71	5.6	150
279	Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimer's and Dementia*, **2015**, 11, 658-71	1.2	146
278	Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. *JAMA Neurology*, **2014**, 71, 1394-404	17.2	129
277	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. *Neurology*, **2012**, 79, 221-8	6.5	124

276	TREM2 is associated with the risk of Alzheimer's disease in Spanish population. *Neurobiology of Aging*, **2013**, 34, 1711.e15-7	5.6	121
275	Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. *Archives of Neurology*, **2011**, 68, 581-6		119
274	Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiology of Aging*, **2016**, 41, 200.e13-200.e20	5.6	119
273	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. *Nature Neuroscience*, **2019**, 22, 1903-1912	25.5	118
272	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. *JAMA Neurology*, **2019**, 76, 264-273	17.2	117
271	Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. *PLoS ONE*, **2014**, 9, e111899	3.7	115
270	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. *Nature Communications*, **2020**, 11, 667	17.4	113
269	TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. *Acta Neuropathologica*, **2009**, 118, 633-45	14.3	110
268	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. *Molecular Neurodegeneration*, **2019**, 14, 1	19	110
267	A statistical framework for cross-tissue transcriptome-wide association analysis. *Nature Genetics*, **2019**, 51, 568-576	36.3	108
266	TREM2 is associated with increased risk for Alzheimer's disease in African Americans. *Molecular Neurodegeneration*, **2015**, 10, 19	19	108
265	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathologica*, **2017**, 133, 839-856	14.3	107
264	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimer's and Dementia*, **2017**, 13, 727-738	1.2	106
263	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. *Molecular Psychiatry*, **2020**, 25, 1859-1875	15.1	106
262	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. *Science Translational Medicine*, **2019**, 11,	17.5	103
261	Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. *ELife*, **2016**, 5,	8.9	100
260	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. *JAMA Neurology*, **2016**, 73, 691-7	17.2	100
259	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. *Nature Medicine*, **2014**, 20, 1452-7	50.5	97

258	SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. *PLoS Genetics*, **2010**, 6, e1001101	6	90
257	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS ONE*, **2014**, 9, e94661	3.7	90
256	TREM2 and neurodegenerative disease. *New England Journal of Medicine*, **2013**, 369, 1568-9	59.2	89
255	Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. *Archives of Neurology*, **2011**, 68, 1013-9		87
254	Missense variant in TREML2 protects against Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 1510.e19-26	5.69	84
253	Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. *PLoS Genetics*, **2014**, 10, e1004758	6	84
252	Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. *PLoS ONE*, **2011**, 6, e26741	3.7	82
251	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease		81
250	The epigenetic landscape of Alzheimer's disease. *Nature Neuroscience*, **2014**, 17, 1138-40	25.5	80
249	Rare variants in FBN1 and FBN2 are associated with severe adolescent idiopathic scoliosis. *Human Molecular Genetics*, **2014**, 23, 5271-82	5.6	78
248	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. *Alzheimer's Research and Therapy*, **2012**, 4, 34	9	78
247	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. *Science Translational Medicine*, **2016**, 8, 341ra76	17.5	77
246	The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. *Science Translational Medicine*, **2019**, 11,	17.5	77
245	C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. *JAMA Neurology*, **2013**, 70, 736-41	11.2	77
244	Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8050-4	11.5	74
243	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. *Alzheimer's and Dementia*, **2018**, 14, 205-214	1.2	70
242	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. *Journal of Neurochemistry*, **2010**, 112, 1305-15	6	68
241	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimer's Research and Therapy*, **2019**, 11, 71	9	66

240	TREM2 and neurodegenerative disease. *New England Journal of Medicine*, **2013**, 369, 1567-8	59.2	66
239	Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. *Neurobiology of Aging*, **2016**, 37, 209.e1-209.e7	5.6	65
238	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. *Acta Neuropathologica*, **2020**, 140, 513-534	14.3	63
237	Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. *PLoS Medicine*, **2014**, 11, e1001713	11.6	62
236	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
235	Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. *Biological Psychiatry*, **2014**, 75, 723-31	7.9	58
234	Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. *PLoS ONE*, **2011**, 6, e15918	3.7	57
233	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. *Nature Medicine*, **2019**, 25, 152-164	50.5	55
232	Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2013**, 34, 2234.e13-9	5.6	54
231	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. *Brain*, **2018**, 141, 1828-1839	11.2	53
230	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nature Medicine*, **2021**, 27, 1187-1196	50.5	51
229	TYROBP genetic variants in early-onset Alzheimer's disease. *Neurobiology of Aging*, **2016**, 48, 222.e9-222.e15	5.6	51
228	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. *Acta Neuropathologica*, **2019**, 137, 879-899	14.3	50
227	Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). *Translational Psychiatry*, **2013**, 3, e256	8.6	50
226	The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. *PLoS Genetics*, **2013**, 9, e1003685	6	49
225	Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. *Journal of Alzheimer's Disease*, **2009**, 18, 603-12	4.3	49
224	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 655-665	1.2	48
223	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. *Brain*, **2016**, 139, 2766-2777	11.2	48

222	Sex-specific genetic predictors of Alzheimer's disease biomarkers. *Acta Neuropathologica*, **2018**, 136, 857-872	14.3	48
221	Palmitoylation-induced aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis. *Journal of Biological Chemistry*, **2012**, 287, 37330-9	5.4	47
220	The role of variation at A□PP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. *Journal of Alzheimer□s Disease*, **2012**, 28, 377-87	4.3	47
219	genotype regulates pathology and disease progression in synucleinopathy. *Science Translational Medicine*, **2020**, 12,	17.5	46
218	Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. *Molecular Neurodegeneration*, **2016**, 11, 29	19	46
217	A polygenic burden of rare variants across extracellular matrix genes among individuals with adolescent idiopathic scoliosis. *Human Molecular Genetics*, **2016**, 25, 202-9	5.6	46
216	Meningeal lymphatics affect microglia responses and anti-A□mmunotherapy. *Nature*, **2021**, 593, 255-260	50.4	45
215	Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. *Journal of Alzheimer□s Disease*, **2010**, 21, 833-42	4.3	43
214	Cortical atrophy and language network reorganization associated with a novel progranulin mutation. *Cerebral Cortex*, **2009**, 19, 1751-60	5.1	42
213	Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease. *Annals of Neurology*, **2016**, 79, 739-747	9.4	42
212	Polygenic risk scores in familial Alzheimer disease. *Neurology*, **2017**, 88, 1180-1186	6.5	41
211	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. *EMBO Molecular Medicine*, **2018**, 10,	12	41
210	Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. *Acta Neuropathologica*, **2017**, 133, 955-966	14.3	40
209	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. *Genome Medicine*, **2017**, 9, 100	14.4	40
208	Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration. *PLoS ONE*, **2013**, 8, e76001	3.7	40
207	Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 955-9	3.5	39
206	Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. *JAMA Network Open*, **2019**, 2, e191350	10.4	37
205	Polygenic risk and hazard scores for Alzheimer's disease prediction. *Annals of Clinical and Translational Neurology*, **2019**, 6, 456-465	5.3	36

204	A missense variant in SLC39A8 is associated with severe idiopathic scoliosis. *Nature Communications*, **2018**, 9, 4171	17.4	36
203	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. *BMC Neurology*, **2017**, 17, 198	3.1	35
202	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. *JAMA Neurology*, **2016**, 73, 1231-1237	17.2	35
201	Parkinson disease is not associated with C9ORF72 repeat expansions. *Neurobiology of Aging*, **2013**, 34, 1519.e1-2	5.6	34
200	Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. *EMBO Molecular Medicine*, **2020**, 12, e12308	12	34
199	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. *Neurobiology of Aging*, **2016**, 46, 235.e1-9	5.6	33
198	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. *Molecular Neurodegeneration*, **2019**, 14, 18	19	32
197	Sex differences in the genetic predictors of Alzheimer's pathology. *Brain*, **2019**, 142, 2581-2589	11.2	32
196	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurology*, **2021**, 78, 102-113	17.2	32
195	Rarity of the Alzheimer disease-protective APP A673T variant in the United States. *JAMA Neurology*, **2015**, 72, 209-16	17.2	31
194	Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. *Neurobiology of Aging*, **2014**, 35, 2681-2690	5.6	31
193	SUCLG2 identified as both a determinator of CSF A□1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. *Human Molecular Genetics*, **2014**, 23, 6644-58	5.6	30
192	A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. *Journal of Alzheimer's Disease*, **2017**, 56, 1037-1054	4.3	29
191	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. *Journal of Alzheimer's Disease*, **2018**, 62, 745-756	4.3	29
190	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. *Neurobiology of Aging*, **2016**, 37, 208.e1-208.e9	5.6	29
189	Alzheimer's disease: rare variants with large effect sizes. *Current Opinion in Genetics and Development*, **2015**, 33, 49-55	4.9	27
188	PATJ Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. *Circulation Research*, **2019**, 124, 114-120	15.7	27
187	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. *Genome Medicine*, **2018**, 10, 43	14.4	26

186	Identification of rare variants in Alzheimer's disease. *Frontiers in Genetics*, **2014**, 5, 369	4.5	26
185	Influence of Coding Variability in APP-A Metabolism Genes in Sporadic Alzheimer's Disease. *PLoS ONE*, **2016**, 11, e0150079	3.7	26
184	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. *Neurobiology of Aging*, **2019**, 75, 42-50	5.6	26
183	Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. *Translational Psychiatry*, **2018**, 8, 265	8.6	26
182	Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. *Alzheimer's and Dementia*, **2014**, 10, 366-71	1.2	25
181	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. *Neurobiology of Aging*, **2011**, 32, 547.e11-6	5.6	25
180	Genetic variants and functional pathways associated with resilience to Alzheimer's disease. *Brain*, **2020**, 143, 2561-2575	11.2	25
179	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
178	The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study. *Experimental Gerontology*, **2011**, 46, 1010-9	4.5	24
177	5'-Upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. *Neurobiology of Disease*, **2009**, 33, 164-70	7.5	24
176	Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate. *Journal of Biological Chemistry*, **2003**, 278, 42710-6	5.4	24
175	Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants. *PLoS ONE*, **2017**, 12, e0185777	3.7	23
174	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. *Neurobiology of Aging*, **2018**, 66, 179.e17-179.e29	5.6	23
173	/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. *Science Translational Medicine*, **2020**, 12,	17.5	23
172	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 1605.e13-20	5.6	22
171	Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors. *Biochemistry*, **2005**, 44, 3535-46	3.2	22
170	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. *Acta Neuropathologica*, **2020**, 139, 45-61	14.3	21
169	Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in European-Americans. *Alzheimer's Research and Therapy*, **2015**, 7, 73	9	20

168	Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate. *Journal of Biological Chemistry*, **2006**, 281, 27744-52	5.4	20
167	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. *Scientific Reports*, **2016**, 6,	4.9	20
166	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. *PLoS Genetics*, **2017**, 13, e1007045	6	19
165	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. *Molecular Psychiatry*, **2021**, 26, 309-321	15.1	19
164	Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype. *JAMA Neurology*, **2019**, 76, 1099-1108	17.2	18
163	TMEM106B: a strong FTLD disease modifier. *Acta Neuropathologica*, **2014**, 127, 419-22	14.3	18
162	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. *Neurobiology of Aging*, **2014**, 35, 1958.e1-2	5.6	18
161	Prospective natural history study of ALS clinical characteristics and biomarkers. *Neurology*, **2019**, 93, e1605-e1617	6.5	17
160	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101767	5.3	16
159	Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. *Dementia and Geriatric Cognitive Disorders*, **2018**, 45, 1-17	2.6	16
158	Discovery and validation of autosomal dominant Alzheimer's disease mutations. *Alzheimer's Research and Therapy*, **2018**, 10, 67	9	16
157	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. *Neurobiology of Disease*, **2020**, 142, 104960	7.5	15
156	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 587-598	6.4	15
155	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. *Stroke*, **2021**, 52, 132-141	6.7	15
154	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. *Annals of Neurology*, **2018**, 84, 424-435	9.4	14
153	SORL1 variants across Alzheimer's disease European American cohorts. *European Journal of Human Genetics*, **2016**, 24, 1828-1830	5.3	14
152	Genetic high throughput screening in Retinitis Pigmentosa based on high resolution melting (HRM) analysis. *Experimental Eye Research*, **2013**, 116, 386-394	3.7	13
151	Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. *Neurology*, **2020**, 95, e3104-e3116	6.5	13

150	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. *Brain*, **2021**, 144, 2176-2185	11.2	13
149	Identification of plexin A4 as a novel clusterin receptor links two Alzheimer's disease risk genes. *Human Molecular Genetics*, **2016**, 25, 3467-3475	5.6	13
148	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. *Annals of Neurology*, **2021**, 89, 254-265	9.4	13
147	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. *PLoS ONE*, **2019**, 14, e0218111	3.7	12
146	Overlapping genetic architecture between Parkinson disease and melanoma. *Acta Neuropathologica*, **2020**, 139, 347-364	14.3	12
145	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. *JAMA Neurology*, **2016**, 73, 1125-32	17.2	12
144	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. *Alzheimer's Research and Therapy*, **2018**, 10, 69	9	11
143	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. *Frontiers in Neuroscience*, **2018**, 12, 230	5.1	11
142	Clinically early-stage CSP□mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. *Acta Neuropathologica Communications*, **2015**, 3, 73	7.3	11
141	Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review. *Journal of Stroke*, **2019**, 21, 276-289	5.6	11
140	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2021**, 17, 618-628	1.2	11
139	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 669-677	5.2	11
138	Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. *Stroke*, **2019**, 50, 1339-1345	6.7	10
137	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 73, 1585-1595	4.3	10
136	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. *Frontiers in Neuroscience*, **2018**, 12, 209	5.1	10
135	Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. *Alzheimer's and Dementia*, **2021**, 17, 1474-1486	1.2	10
134	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-□Burden in Cognitively Normal Individuals in Late-Life. *Journal of Alzheimer's Disease*, **2019**, 69, 817-827	4.3	9
133	Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. *Alzheimer's and Dementia*, **2020**, 16, 1134-1145	1.2	9

132	Genomic and multi-tissue proteomic integration for understanding the biology of disease and other complex traits		9
131	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. *Nature Neuroscience*, **2021**, 24, 1302-1312	25.5	9
130	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. *BMC Neurology*, **2016**, 16, 217	3.1	9
129	TMEM230 in Parkinson's disease. *Neurobiology of Aging*, **2017**, 56, 212.e1-212.e3	5.6	8
128	An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. *Neurobiology of Aging*, **2018**, 66, 178.e1-178.e8	5.6	8
127	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. *Neurology* , **2019**, 93, e851-e863	6.5	8
126	Cruchaga & Goate reply. *Nature*, **2015**, 520, E5-6	50.4	8
125	Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning. *Information Fusion*, **2020**, 58, 153-167	16.7	8
124	Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. *Acta Neuropathologica*, **2021**, 142, 689-706	14.3	8
123	Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. *Alzheimer's Research and Therapy*, **2018**, 10, 86	9	8
122	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. *JAMA Network Open*, **2019**, 2, e1913491	10.4	7
121	Genetic discoveries in AD using CSF amyloid and tau. *Current Genetic Medicine Reports*, **2014**, 2, 23-29	2.2	7
120	Biobank-wide association scan identifies risk factors for late-onset Alzheimer's disease and endophenotypes		7
119	Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke. *Stroke*, **2020**, 51, 2454-2463	6.7	7
118	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. *Neurology: Genetics*, **2021**, 7, e571	3.8	7
117	CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. *Experimental Gerontology*, **2017**, 90, 83-89	4.5	6
116	CpG-related SNPs in the MS4A region have a dose-dependent effect on risk of late-onset Alzheimer disease. *Aging Cell*, **2019**, 18, e12964	9.9	6
115	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. *Brain Communications*, **2020**, 2, fcaa102	4.5	6

114	Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma. *Brain*, **2021**, 144, 2416-2426	11.2	6
113	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nature Communications*, **2021**, 12, 5346	17.4	6
112	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. *Neurobiology of Aging*, **2018**, 70, 325.e1-325.e5	5.6	5
111	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. *Scientific Reports*, **2019**, 9, 10854	4.9	5
110	Novel progranulin variants do not disrupt progranulin secretion and cleavage. *Neurobiology of Aging*, **2013**, 34, 2538-40	5.6	5
109	Variant-dependent heterogeneity in amyloid burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.. *Lancet Neurology, The*, **2022**, 21, 140-152	24.1	5
108	, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. *Neurology*, **2020**, 95, e3288-e3302	6.5	5
107	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. *Alzheimer Disease and Associated Disorders*, **2020**, 34, 212-219	2.5	5
106	The Dystonia Coalition: A Multicenter Network for Clinical and Translational Studies. *Frontiers in Neurology*, **2021**, 12, 660909	4.1	5
105	Plasma amyloid levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants. *Alzheimer's and Dementia*, **2021**, 17, 1663-1674	1.2	5
104	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke. *Thrombosis and Haemostasis*, **2016**, 116, 1165-1171	7	5
103	Exome-wide rare variant analysis in familial essential tremor. *Parkinsonism and Related Disorders*, **2021**, 82, 109-116	3.6	5
102	Neuronal VCP loss of function recapitulates FTLD-TDP pathology. *Cell Reports*, **2021**, 36, 109399	10.6	5
101	Modeling autosomal dominant Alzheimer's disease with machine learning. *Alzheimer's and Dementia*, **2021**, 17, 1005-1016	1.2	5
100	Remote cognitive assessment approaches in the Dominantly Inherited Alzheimer Network (DIAN). *Alzheimer's and Dementia*, **2020**, 16, e038144	1.2	4
99	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). *Alzheimer's and Dementia*, **2020**, 16, 219-228	1.2	4
98	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. *Stroke*, **2019**, 50, 3618-3621	6.7	4
97	Precision genome-editing with CRISPR/Cas9 in human induced pluripotent stem cells		4

96	The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk		4
95	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. *Acta Neuropathologica Communications*, **2020**, 8, 196	7.3	4
94	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. *Journal of Alzheimer's Disease*, **2020**, 77, 1469-1482	4.3	4
93	O1-04-03: COMPARING SMARTPHONE-ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE **2018**, 14, P224-P225		4
92	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. *Neurology*, **2021**, 96, e1632-e1645	6.5	4
91	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. *Lancet Neurology, The* , **2022**, 21, 329-341	24.1	4
90	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. *Methods in Molecular Biology*, **2016**, 1303, 299-314	1.4	3
89	Cruchaga & Goate reply. *Nature*, **2015**, 520, E10	50.4	3
88	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. *Alzheimer's and Dementia*, **2020**, 16, e041129	1.2	3
87	A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer. *Biochemical Journal*, **2007**, 405, 165-71	3.8	3
86	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.. *Journal of Clinical and Experimental Neuropsychology*, **2022**, 1-13	2.1	3
85	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. *Biological Psychiatry*, **2021**, 89, 825-833	7.9	3
84	Causal Effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 Levels on Ischemic Stroke: A Mendelian Randomization Study. *Stroke*, **2021**, 52, e316-e320	6.7	3
83	Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease **2021**,		3
82	Rare and de novo coding variants in chromodomain genes in Chiari I malformation. *American Journal of Human Genetics*, **2021**, 108, 100-114	11	3
81	Solanezumab in-depth outcomes. *Alzheimer's and Dementia*, **2020**, 16, e038028	1.2	2
80	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease		2
79	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. *Psychological Science*, **2021**, 32, 849-860	7.9	2

78	Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau. *Alzheimer's and Dementia*, **2021**,	1.2	2
77	A Multi-center Genome-wide Association Study of Cervical Dystonia. *Movement Disorders*, **2021**,	7	2
76	Advances in Genetic and Molecular Understanding of Alzheimer's Disease. *Genes*, **2021**, 12,	4.2	2
75	Cell specific peripheral immune responses predict survival in critical COVID-19 patients.. *Nature Communications*, **2022**, 13, 882	17.4	2
74	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	2
73	Gantenerumab in-depth outcomes. *Alzheimer's and Dementia*, **2020**, 16, e038049	1.2	1
72	Protective genetic variants in the MS4A gene cluster modulate microglial activity. *Alzheimer's and Dementia*, **2020**, 16, e039431	1.2	1
71	P1-045: EXOME ARRAY ANALYSIS IDENTIFIES NOVEL RISK VARIANTS FOR ALZHEIMER'S DISEASE WITH ONSET BEFORE 65 YEARS **2014**, 10, P319-P319		1
70	O4□1□1: Association of genetic variants with cerebrospinal fluid protein levels of ACE, MMP3 and other proteins and risk for Alzheimer's disease **2013**, 9, P677-P678		1
69	P1-055: Exome-sequencing in a large dataset of late-onset families with Alzheimer's disease **2015**, 11, P359-P359		1
68	Murine roseolovirus does not accelerate amyloid-□pathology and human roseoloviruses are not over-represented in Alzheimer disease brains.. *Molecular Neurodegeneration*, **2022**, 17, 10	19	1
67	Genetic Variants and Functional Pathways Associated with Resilience to Alzheimer□ Disease		1
66	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure		1
65	The TMEM106B rs1990621 protective variant is also associated with increased neuronal proportion		1
64	Polygenic Risk Score of Sporadic late Onset Alzheimer Disease Reveals a Shared Architecture with the Familial and Early Onset Forms		1
63	Synchronized genetic activities in Alzheimer□ brains revealed by heterogeneity-capturing network analysis		1
62	Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer□ Disease		1
61	Gene-Based Analysis in HRC Imputed Genome Wide Association Data Identifies Three Novel Genes For Alzheimer□ Disease		1

60	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain		1
59	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. *Scientific Reports*, **2020**, 10, 12184	4.9	1
58	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12038	5.2	1
57	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. *Neurobiology of Disease*, **2021**, 151, 105247	7.5	1
56	Alzheimer's Disease Alters Oligodendrocytic Glycolytic and Ketolytic Gene Expression. *FASEB Journal*, **2021**, 35,	0.9	1
55	Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. *Neurobiology of Aging*, **2021**, 102, 64-72	5.6	1
54	Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
53	Lack of evidence supporting a role for DPP6 sequence variants in Alzheimer's disease in the European American population. *Acta Neuropathologica*, **2021**, 141, 623-624	14.3	1
52	Regional age-related atrophy after screening for preclinical alzheimer disease. *Neurobiology of Aging*, **2021**, 109, 43-51	5.6	1
51	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI		1
50	Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke.. *Science Translational Medicine*, **2022**, 14, eabk0135	17.5	1
49	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. *NeuroImage*, **2022**, 119228	7.9	1
48	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. *PLoS ONE*, **2022**, 17, e0267298	3.7	1
47	Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease. *Human Molecular Genetics*, **2021**, 30, 811-822	5.6	0
46	Long runs of homozygosity are associated with Alzheimer's disease. *Translational Psychiatry*, **2021**, 11, 142	8.6	0
45	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease.. *Acta Neuropathologica Communications*, **2022**, 10, 29	7.3	0
44	Global system segregation enhances reserve in normal aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e037930	1.2	
43	Late-onset Alzheimer's disease-associated gene, CPAMD8, increases B-CTF and affects APP processing through regulation of the autophagy-lysosome pathway. *Alzheimer's and Dementia*, **2020**, 16, e040559	1.2	

42	Alzheimer-associated circular RNA circHOMER1 regulates synaptic gene expression and cognition. *Alzheimer's and Dementia*, **2020**, 16, e042335	1.2
41	Orderings of biomarker changes for Alzheimer disease in cognitively normal individuals from 18 to 101 years of age. *Alzheimer's and Dementia*, **2020**, 16, e043187	1.2
40	A comprehensive analysis of dementia cerebrospinal fluid biomarkers using GWAs, polygenic risk scores and Mendelian randomization in Parkinson's disease. *Alzheimer's and Dementia*, **2020**, 16, e043233	1.2
39	Prediction of Alzheimer's disease using plasma RNA sequences. *Alzheimer's and Dementia*, **2020**, 16, e043273	1.2
38	Proteogenomic analysis of cerebrospinal fluid reveals causal role of proteins from the autophagy-lysosome pathway in Parkinson's disease. *Alzheimer's and Dementia*, **2020**, 16, e043422	1.2
37	Multiomics approaches reveal a link between the MS4A gene loci, TREM2, and microglia function. *Alzheimer's and Dementia*, **2020**, 16, e043592	1.2
36	Identification of blood eQTLs for AD risk loci. *Alzheimer's and Dementia*, **2020**, 16, e043801	1.2
35	O2-10-05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease **2016**, 12, P252-P252	
34	O2-12-04: ALZHEIMER'S DISEASE RISK VARIANTS IN PHOSPHOLIPASE D3 ALTER APP METABOLISM BY GAMMA-DEPENDENT AND GAMMA-INDEPENDENT MECHANISMS **2014**, 10, P192-P192	
33	O1-04-02: EXOME-SEQUENCING IN LATE-ONSET FAMILIES IDENTIFIED ADDITIONAL CANDIDATES GENES FOR ALZHEIMER'S DISEASE **2014**, 10, P135-P135	
32	O1-04-05: NOVEL CODING VARIANTS IN TREM2 INCREASE RISK FOR ALZHEIMER'S DISEASE **2014**, 10, P136-P136	
31	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P41-P41	
30	F2-01-03: A rare coding variant in PLD3 confers high risk for Alzheimer's disease **2013**, 9, P312-P312	
29	[IC-P-057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P47-P47	
28	[P2-372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P768-P769	
27	[P3-094]: RESOURCE OF MULTIPLEX AFRICAN AMERICAN FAMILIES FOR WHOLE-GENOME SEQUENCING **2017**, 13, P970-P970	
26	[P3-257]: DECODING VARIABILITY IN AGE-AT-SYMPTOMATIC-ONSET BETWEEN PARENTS AND CHILDREN WITH SPORADIC ALZHEIMER DISEASE DEMENTIA **2017**, 13, P1041-P1042	
25	[IC-P-061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P50-P50	

24	[IC-P-166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P125-P126	
23	[P2-045]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P754-P754	
22	[O1-11-03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE **2017**, 13, P218-P219	
21	[O2-08-05]: NOVEL CANDIDATE VARIANTS IN LOAD DETECTED BY THE FAMILIAL ALZHEIMER SEQUENCING (FASE) PROJECT **2017**, 13, P572-P573	
20	[O2-18-02]: PHOSPHOLIPASE D3 CONTRIBUTES TO ALZHEIMER's DISEASE RISK VIA DISRUPTION OF A CLEARANCE THROUGH THE LYSOSOME **2017**, 13, P602-P603	
19	[O1-02-04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P186-P187	
18	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P172-P172	
17	Replication study of AD-associated rare variants.. *Alzheimer's and Dementia*, **2022**,	1.2
16	Single-nuclei RNA-seq of brains carriers of high-risk variants and Mendelian mutations. *Alzheimer's and Dementia*, **2020**, 16, e043125	1.2
15	P1-221: Dynamic Relationships Between Big Five Personality Traits, Alzheimer's Disease Biomarkers, and Cognition in Autosomal Dominant Alzheimer's Disease **2016**, 12, P491-P492	
14	F1-01-02: Alzheimer's Disease Sequencing Project: Search for Alzheimer's Disease Resilience Genes That May Modify Disease Susceptibility in Specific Apoe Genotype Backgrounds **2016**, 12, P162-P163	
13	P3-097: SORL1 Variants Across Alzheimer's Disease Cohorts in European Americans **2016**, 12, P857-P857	
12	P4-487: BRAIN SOMATIC MOSAICISM IN 17Q21.31 MAPT H1-ASSOCIATED ALZHEIMER'S DISEASE **2019**, 15, P1499-P1499	
11	IC-P-023: EARLY RESTING-STATE NETWORK DYSFUNCTION IN APOE 4 CARRIERS WITHOUT BIOMARKER EVIDENCE OF ALZHEIMER'S DISEASE IS RELATED TO SUBCLINICAL TAU CHANGES **2019**, 15, P30-P31	
10	P1-173: BRAIN TRANSCRIPTOMICS STUDY REVEALS DIFFERENTIAL EXPRESSION OF THE THREE TREM2 TRANSCRIPT IN AD AND TREM2 MUTATION CARRIERS **2018**, 14, P345-P345	
9	P3-494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES **2018**, 14, P1311-P1311	
8	P2-105: NOMINATION OF NOVEL CANDIDATE GENES FOR FAMILIAL LATE ONSET ALZHEIMER DISEASE AFTER EVALUATION OF GENE-BASED FAMILY-BASED METHODS **2018**, 14, P709-P709	
7	O4-01-04: CIRCULAR RNAS IN ALZHEIMER'S DISEASE BRAIN TISSUES **2018**, 14, P1401-P1401	

List of Publications

6	P1-139: THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY **2018**, 14, P327-P328	
5	S1-02-01: REVIEW OF GWAS GENES AND POLYGENIC RISK SCORES **2018**, 14, P198-P198	
4	P2-295: QUANTIFYING THE CONTRIBUTIONS OF HERITABLE AND NON-HERITABLE FACTORS TO AGE-AT-ONSET OF ALZHEIMER DEMENTIA IN ADULT CHILDREN OF AFFECTED PARENTS **2018**, 14, P794-P795	
3	O5-04-03: IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES AND POTENTIALLY NOVEL DRUGS FOR FRONTOTEMPORAL LOBAR DEMENTIA WITH TAU INCLUSIONS BY A DEPENDABLE ANALYSIS APPROACH **2018**, 14, P1651-P1652	
2	Integrating functional genomics with genetics to understand the biology of ALS and FTD.. *Med*, **2022**, 3, 226-227	31.7
1	Impact of MAPT mutations on transcriptomic signatures of FTLD brains and patient-derived pluripotent cell models.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 2, e058313	1.2